| Literature DB >> 35920918 |
Yanhua Bai1, Ting Guo2, Dongfeng Niu3, Yanli Zhu3, Wenhao Ren3, Qian Yao3, Xiaozheng Huang3, Qin Feng3, Tianxiao Wang4, Xiuli Ma3, Xinqiang Ji5.
Abstract
Immunotherapy shows prospects in treating advanced medullary thyroid carcinoma although controversial reports are present. Recently, histological grading has been applied to medullary thyroid carcinoma by the Ki-67 index, mitotic figures, and tumor necrosis. However, the interrelation of PD-L1 expression, the Ki-67 index, and major genetic alterations of sporadic medullary thyroid carcinoma has not been fully reported. We examined the expression of PD-L1 (SP142 and 22C3) and the Ki-67 index immunohistologically and detected the major genetic alterations by next-generation sequencing in a cohort of sporadic medullary thyroid carcinomas, studied their survival impact, and discussed their interrelation. We identified that a high Ki-67 index (> 2%) and positive RET M918T mutation were correlated with poor disease-free survival but were not correlated with PD-L1 expression. All PD-L1 positive tumors were RET M918T mutation negative, and PD-L1 expression was positively correlated with HRAS mutation. The Ki-67 index was correlated with neither PD-L1 expression nor major genetic alterations. Our results indicate that immunotherapy targeting PD-L1/PD-1 might be more effective for patients with sporadic medullary thyroid carcinoma harboring HRAS mutations.Entities:
Keywords: Ki-67 index; Medullary thyroid carcinoma; PD-L1; RAS; RET
Year: 2022 PMID: 35920918 DOI: 10.1007/s00428-022-03390-9
Source DB: PubMed Journal: Virchows Arch ISSN: 0945-6317 Impact factor: 4.535